See-Saw: Challenger Natco Is Now Licensee For Lilly’s Baricitinib

 
• By Anju Ghangurde
  
see-saw
Lilly ropes in Natco as licensee for baricitinib • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from India

More from Focus On Asia